Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $231

摩根士丹利維持艾伯維公司(ABBV.US)買入評級，上調目標價至231美元

moomoo資訊 · 2024/10/31 09:31 · 評級/大行評級

Morgan Stanley analyst Terence Flynn maintains $AbbVie (ABBV.US)$ with a buy rating, and adjusts the target price from $218 to $231.

According to TipRanks data, the analyst has a success rate of 56.3% and a total average return of 9.5% over the past year.

AnalystRecentRatingAutoNews_206654_20241031_c580efca8787d61123ba14589e335a874ba18e85_1730457013513473_mm_en

Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:

AbbVie delivered another notable quarter, and attention is now shifting towards emraclidine and the outlook for 2025.
Following solid Q3 results and a rise in 2024 revenue guidance, expectations for AbbVie's performance towards the end of the year are optimistic. This optimism is reflected in an enhanced 2025 EPS outlook. However, when weighing the company's long-term growth prospects against its present valuation, a balanced view is maintained.
Following AbbVie's 'beat and raise' performance in their Q3 report, there is a growing confidence in the company's growth outlook. This is largely due to increased projections for Rinvoq and Skyrizi, which somewhat counterbalance the anticipated declines in aesthetics and Humira sales.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根士丹利分析師Terence Flynn維持$艾伯維公司 (ABBV.US)$買入評級，並將目標價從218美元上調至231美元。

根據TipRanks數據顯示，該分析師近一年總勝率為56.3%，總平均回報率為9.5%。

AnalystRecentRatingAutoNews_206654_20241031_c580efca8787d61123ba14589e335a874ba18e85_1730457013513473_mm_tc

此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：

艾伯維又迎來了一個引人注目的季度，現在注意力正轉移到emraclidine和2025年的展望上。
繼第三季度業績穩健和2024年收入預期上調之後，對艾伯維年底表現的預期令人樂觀。這種樂觀情緒反映在2025年每股收益前景的增強中。但是，在權衡公司的長期增長前景與其目前的估值時，保持了平衡的觀點。
繼艾伯維在第三季度報告中表現出「超越並上漲」的表現之後，人們對公司的增長前景越來越有信心。這主要是由於對Rinvoq和Skyrizi的預測增加，這在一定程度上抵消了美學和Humira銷售額的預期下降。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $231

Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $231

風險及免責聲明

聲明